BURLINGTON, Mass. , Oct. 29, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in the 2026 Jefferies Global Healthcare Conference in London . 2026 Jefferies Global Healthcare Conference Dates: Monday, November 16 & Tuesday, November 17, 2026 Format: Fireside chat and 1x1 meetingsFireside Chat: Monday, November 16, 2026 from 4:00 – 4:25 p.m. GMT Location: London, UK If you are interested in meeting with the Minerva team during the conference, please reach out to your respective Jefferies representative. The live webcast can be accessed in the events section of the Minerva Neurosciences website HERE . Access to the webcast replay will be available approximately two hours after the completion of the event and will be archived on the Company’s website. About Minerva Neurosciences Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is conducting a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website . Contacts: Frederick Ahlholm Chief Financial OfficerMinerva Neurosciences, Inc. FAhlholm@minervaneurosciences.com Corey Davis, Ph.D. LifeSci Advisors, LLC212-915-2577 cdavis@lifesciadvisors.com Source: Minerva Neurosciences, Inc The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.